Safety and immunogenicity of an MF59-adjuvanted spike  glycoprotein-clamp vaccine for SARS-CoV-2 :   a randomised,  double-blind, placebo-controlled, phase 1 trial / 
Keith J Chappell [and twenty four others] 
<br/><br/>Lancet Infect Dis . 2021 Apr 19;S1473-3099 (21) 00200-0. <br/>doi: 10.1016/S1473-3099(21)00200-0. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>COVID-19 Vaccines--immunology<br/>Placebo Effects<br/>Adjuvants, Immunologic